Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy — Stella

Home/IgA Nephropathy/Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

View on ClinicalTrials.gov

Recruiting

Back to IgA Nephropathy trials

Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Peking University First Hospital, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing

Sponsor

Keymed Biosciences Co.Ltd

Enrollment target

~70 participants

Started

May 2023

Primary completion

June 2027

Age range

18 Years – 75 Years

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.